Riskpilot← Back to searchSign inGet full accessAstellas Pharma AB
ABActiveOrg 5564587003MalmöWholesale of pharmaceutical and medical goods · NACE 4646Est. 199211 employees
Revenue 2025
SEK 49,7M
+1406% vs 2024
EBITDA margin
2.0%
+1845% vs 2024
Equity ratio
46.9%
Financial strength
Net profit 2025
SEK 347K
+155% vs 2024
| Revenue | SEK 49,7M | +1406% |
| EBITDA | SEK 992K | +1845% |
| Net profit | SEK 347K | +155% |
| Total assets | SEK 86,5M | +1301% |
| Equity | SEK 40,6M | +1063% |
| Employees | 11 | — |
Legal name
Astellas Pharma AB
Org number
5564587003
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
28 december 1992
Share capital
SEK 252 000
Employees
11 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är att utveckla, tillverka och bedriva handel med produkter och immateriella rättigheter inom hälso- och sjukvårdsområdet, att etablera, förvärva och finansiera andra affärsföretag samt idka annan därmed förenlig verksamhet. Bolaget skall dock inte bedriva sådan rörelse som avsågs i bankaktiebolags-, kreditaktiebolags- eller i bankrörelselagen.
Address
Malmö
Phone
+46406501500
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 48 028 | 41 152 | 43 802 | 3 298 | 49 672 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 2 426 | 1 509 | 2 155 | 51 | 992 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 2 426 | 1 509 | 2 155 | 51 | 992 |
| Net financials | −133 | −42 | −158 | 24 | 66 |
| Profit before tax | 2 294 | 1 468 | 1 997 | 75 | 1 057 |
| Tax | −809 | −796 | −1 681 | 61 | −710 |
| Net profit | 1 485 | 672 | 316 | 136 | 347 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 43 543 | 45 224 | 56 098 | 6 177 | 86 521 |
| Equity | 33 367 | 34 360 | 37 820 | 3 488 | 40 551 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10 177 | 10 864 | 18 277 | 2 689 | 45 970 |
| Total debt | 10 177 | 10 864 | 18 277 | 2 689 | 45 970 |
EBITDA margin
2.0%
This company
15.8%
Market median
-87% vs market
20212025
Equity ratio
46.9%
This company
38.2%
Market median
+23% vs market
20212025
Return on equity
0.9%
This company
18.4%
Market median
-95% vs market
20212025
Net profit margin
0.7%
This company
8.1%
Market median
-91% vs market
20212025
Asset turnover
0.57×
This company
1.12×
Market median
-49% vs market
20212025
Debt / equity
1.13×
This company
0.62×
Market median
-82% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PA Chief Auditor | Chief Auditor | 2020 |
| Former (1) | ||
CM Authorized Recipient of Service | Authorized Recipient of Service | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2025 | |
| Board of Directors | 2022 | |
| Former (6) | ||
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Chairman | 2025 – 2025 | |
| Chairman | 2020 – 2022 | |
| Chairman | 2022 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ASTELLAS PHARMA EUROPE LTD
Astellas Pharma AB (this company)Board members of Astellas Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Magnus Svernlöv | Authorized Recipient of Service | 0 companies |
| Pia Agneta Anell | Chief Auditor | 0 companies |
| Damla Ebru Atilgan | Board of Directors | 0 companies |
| Yagnaram Santharam | Board of Directors | 0 companies |
| Pedro Möllebro | Board of Directors | 0 companies |
| Daniel Benjamin Matthias Schulze | Board of Directors | 0 companies |
| Morten Auscher | Chairman | 0 companies |
| Pia Teresa Lindkvist | Chairman | 0 companies |
| Mark Andree Dekker | Chairman | 0 companies |
| Eva Louise Carmén Ekedahl | Board of Directors | 0 companies |
| Karl Håkan Lennart Widén | Chairman | 0 companies |